In a report released yesterday, Julian Harrison from BTIG reiterated a Buy rating on Aclaris Therapeutics (ACRS – Research Report), with a price target of $32.00. The company’s shares closed last Friday at $16.55.
Harrison covers the Healthcare sector, focusing on stocks such as Outlook Therapeutics, Keros Therapeutics, and Prometheus Biosciences. According to TipRanks, Harrison has an average return of 20.7% and a 54.05% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aclaris Therapeutics with a $34.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
ACRS market cap is currently $1.1B and has a P/E ratio of -12.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
Read More on ACRS: